Investment Rating - The report maintains a "BUY" rating for Greentown Management with a target price of HK$ 9.37, reflecting a 13x 2024E PE [2][4]. Core Insights - Greentown Management achieved a net profit growth of +31% YoY in FY23, with a maintained dividend payout ratio of 100%, resulting in an 8% dividend yield [2][5]. - The company is expected to guide industry-leading growth with a revenue CAGR of +20% and net profit CAGR of +25% over the next three years, potentially outperforming the broader property market [2][8]. - The company's adaptability in business restructuring has been highlighted as a key factor in its strong performance despite a sluggish property market [2][8]. Financial Performance Summary - FY23 results showed revenue of RMB 3,302 million, a 24.3% increase YoY, and attributable net profit of RMB 974 million, up 31% YoY [3][5]. - Gross profit margin remained stable at 52%, with a slight decrease in commercial project management (PJM) margin to 52% and an improvement in government PJM margin to 45% [5][12]. - The company reported a net margin of 29.5% in FY23, reflecting a 1 percentage point increase from the previous year [5][12]. Future Projections - Revenue is projected to reach RMB 4,048 million in FY24, with a YoY growth of 22.6%, and net profit is expected to be RMB 1,250.9 million, reflecting a 28.5% increase [3][7]. - The company has a billable contract value of RMB 25 billion, with an expected annual increase of approximately RMB 10 billion [2][8]. - The forecast for net profit in FY26 is RMB 1,897.3 million, indicating a continued growth trajectory [3][12]. Market Position and Strategy - Greentown Management has expanded its business into non-residential projects, which accounted for 15% of new contracts in FY23, in response to a contracting residential market [2][8]. - The company has successfully maintained its market share in the property management sector, with newly contracted gross floor area (GFA) increasing to 35.3 million square meters in FY23 [10][11]. - The report emphasizes the company's asset-light model and high cash flow as significant advantages in the current market environment [2][8].

Investment Rating - The report maintains a "BUY" rating for Zhejiang Dingli with a target price of RMB70, representing an upside of 24.8% from the current price of RMB56.10 [2]. Core Insights - Zhejiang Dingli plans to invest RMB1.7 billion to build a new production base for 20,000 units of new energy aerial work platforms (AWP), which is expected to enhance its global competitiveness [2]. - The new capacity is projected to contribute approximately RMB2.5 billion in annual sales once operational, with completion expected in 36 months [2]. - The company has sufficient internal resources to finance the capital expenditure without needing equity financing [2]. Financial Performance Summary - Revenue is expected to grow from RMB5,445 million in FY22 to RMB6,267 million in FY23, and further to RMB7,508 million in FY24, reflecting a year-on-year growth of 15.1% and 19.8% respectively [9]. - Net profit is projected to increase from RMB1,257 million in FY22 to RMB1,693 million in FY23, and RMB1,963 million in FY24, indicating a growth rate of 34.7% [9]. - The earnings per share (EPS) is forecasted to rise from RMB2.48 in FY22 to RMB3.34 in FY23, and RMB3.88 in FY24, showing a year-on-year growth of 34.7% [9]. Capacity Expansion and Market Position - The new production base will add 30% capacity by 2026-27, focusing on scissors lifts to meet rising demand for electric and advanced models in overseas markets [2]. - Dingli currently operates five production bases, and the new facility will require acquiring additional land in Deqing, Zhejiang [2]. - The company is positioned to benefit from the increasing demand for aerial work platforms, particularly in international markets [2]. Revenue Breakdown and Growth Projections - The revenue from core business segments is expected to grow significantly, with boom lifts projected to generate RMB2,250 million in FY24 and scissor lifts expected to reach RMB4,419 million [4]. - The average gross margin for the core business is anticipated to improve from 29.4% in FY22 to 36.5% in FY24 [4]. - The overall revenue growth rate is projected to stabilize around 15.2% in FY25, indicating sustained demand and operational efficiency [12].

M N 22 Mar 2024 CMB International Global Markets | Equity Research | Company Update Innovent Biologics (1801 HK) More than obesity  Strong product sales in FY23. In FY23, Innovent recorded total revenue of Target Price HK$55.00 RMB6.21bn, including RMB5.73bn product sales revenue (+38.4% YoY), in line with (Previous TP HK$57.35) our expectation. Innovent had a strong 2H23, with product sales +33.1% HoH vs the Up/Downside 44.4% first half. As per Eli Lilly, total sales of sintilimab in FY23 reached US$393.3 ...

Investment Rating - The report maintains a "BUY" rating for Intron Tech with a new target price (TP) of HK$5.53, based on a 12x FY24E P/E valuation methodology [13][14][21]. Core Insights - Intron's FY23 revenue was RMB 5.8 billion, reflecting a 20% year-over-year (YoY) growth, while net income decreased by 23.5% YoY to RMB 317 million. The gross profit margin (GPM) was 18.7%, down 2.8 percentage points YoY, attributed to intensified price competition [21][32]. - The company expects solid growth in the New Energy Vehicle (NEV) and Hybrid Electric Vehicle (HEV) segments, driven by increasing demand and export opportunities in China. However, margin pressure may persist due to heightened competition [21][32]. - The report highlights a significant increase in R&D expenses, which reached 9.0% of revenue due to talent recruitment and upfront investments. Management anticipates a normalization of these expenses in FY24E [21][32]. Revenue Forecasts - Revenue is projected to grow from RMB 6,975 million in FY24E to RMB 10,805 million in FY26E, with a YoY growth rate of 20.2% in FY24E and 24.2% in FY25E [21][26]. - The breakdown of revenue by segment shows strong growth in New Energy (131.6% YoY in 2021, 91.0% in 2022) and Automation & Connectivity (151.3% YoY in 2022) [21][26]. Earnings Summary - The earnings forecast for FY24E includes a revenue estimate of RMB 6,975 million, a gross profit of RMB 1,298 million, and a net profit of RMB 441 million, indicating a 39% YoY growth in net profit [21][26][32]. - The report notes that the EPS for FY24E is expected to be RMB 0.41, with a consensus estimate of RMB 0.55 for FY25E [21][26]. Valuation Metrics - Intron is currently trading at 4.5x FY24E P/E, significantly lower than the average P/E of 22.8x for its peers, indicating that it is undervalued [14][21]. - The report emphasizes the attractive risk/reward profile of Intron, especially in light of potential catalysts such as favorable NEV policies and increasing penetration of Advanced Driver Assistance Systems (ADAS) [14][21].

Investment Rating - The report maintains a "BUY" rating for Prudential Plc with a target price adjusted to HK$137.8, reflecting a potential upside of 81.9% from the current price of HK$75.75 [2][3]. Core Insights - Prudential reported a strong FY23 performance with new business profit (NBP) increasing by 45% year-over-year (YoY) to US$3.13 billion, surpassing consensus estimates by 6.4% [2]. - The NBP margin expanded by 3 percentage points to 53% for the full year, with a notable improvement in the second half of FY23, where the margin reached 57% [2]. - The board approved a full-year dividend of US$0.2 per share, indicating a 9% increase from FY22, and expects continued dividend per share (DPS) growth of 7%-9% in FY24 [2]. Summary by Sections Financial Performance - FY23 net profit was US$1.7 billion, a significant recovery from a loss of US$1.0 billion in FY22 [3]. - The adjusted operating profit for FY23 grew by 8% YoY to US$2.9 billion, driven by lower central costs and restructuring expenses [2][3]. - The Group's total assets increased to US$174.1 billion in FY23, with a projected growth to US$198.6 billion by FY24 [8]. Business Segments - Agency NBP surged by 75% YoY to US$2.1 billion, supported by a 37% growth in Health & Protections (H&P) and a 59% increase in agent productivity [2]. - The bancassurance segment saw a decline of 8% to US$793 million, primarily due to poor performance in China and Vietnam [2]. - The NBP of the China joint venture, CITIC Prudential Life, fell by 43% YoY to US$222 million, impacted by a 40% decline in APE sales [2]. Valuation Metrics - The stock is currently trading at a price-to-embedded value (P/EV) of 0.54x for FY24E, close to historical lows, reflecting concerns over China exposure and trading liquidity [2][3]. - The expected return on equity (ROE) is projected to improve from 9.8% in FY23 to 12.5% by FY26 [9]. - The dividend yield is anticipated to rise from 1.6% in FY23 to 2.7% by FY26 [9].

M N 22 Mar 2024 CMB International Global Markets | Equity Research | Company Update Sunny Optical (2382 HK) Expectations reset on conservative guidance; Maintain HOLD Target Price HK$47.31 Sunny Optical (Sunny)’s FY23 net profit was largely in-line with profit warning, but (Previous TP HK$50.71) 2H23 GPM of 14.1% (vs 19% in 2H22) was below expectations due to more intense Up/Downside 1.0% competition despite spec upgrade and more high-end models in 2H23. For 2024 Current Price HK$46.85 guidance, while mgmt. ...

Investment Rating - The report maintains a BUY rating for FriendTimes, with a target price of HK$1.8, indicating an upside potential of 80% from the current price of HK$1.00 [13][29]. Core Insights - FriendTimes reported a significant revenue decline of 31% YoY for FY23, with an adjusted net loss of RMB 133 million, which was largely in line with expectations. The decline was attributed to existing games' grossing decline and increased sales and marketing expenses [29]. - The new game "Twist of the Fate 2" (ToF2) has shown promising performance, ranking in the top 50-70 for iOS grossing in Q1 2024. The company expects ToF2 to maintain stable grossing and is focusing on expanding to Android and overseas markets [29]. - Management is prioritizing cost discipline in FY24, with adjustments in personnel and careful development of high-R&D projects. The report anticipates that mini-games will unlock additional grossing potential [29]. Financial Summary - For FY22, revenue was RMB 1,524 million, which decreased to RMB 1,056 million in FY23, with a projected recovery to RMB 1,474 million in FY24, and further growth to RMB 1,933 million in FY25 and RMB 2,048 million in FY26 [1][23]. - Adjusted net profit is expected to recover from a loss of RMB 131.8 million in FY23 to a profit of RMB 180.3 million in FY24, increasing to RMB 256.9 million in FY25 and RMB 299.4 million in FY26 [1][23]. - The report indicates a significant drop in diluted EPS from 1.90 cents in FY22 to a loss of 6.10 cents in FY23, with a forecasted recovery to 8.27 cents in FY24 and further increases in subsequent years [1][23]. Valuation Metrics - The P/E ratio is projected to decrease from 50.7 in FY22 to 11.1 in FY24, indicating a more favorable valuation as earnings recover [1][25]. - The gross margin is expected to stabilize around 68% from FY24 onwards, while the operating margin is projected to improve gradually [30][25]. - The report highlights a current ratio of 4.1 in FY23, indicating strong liquidity, which is expected to improve to 5.4 in FY24 [25].

Investment Rating - The report maintains a "BUY" rating for CSPC Pharmaceutical, with a target price revised to HK$7.76 from HK$8.16, indicating a potential upside of 21.1% from the current price of HK$6.41 [2][4]. Core Insights - CSPC reported FY23 revenue of RMB31.45 billion, reflecting a 1.7% year-over-year growth, and an attributable net profit of RMB5.87 billion, down 3.6% year-over-year. The adjusted net profit increased by 2.8% year-over-year to RMB6.28 billion [2]. - The company expects new products to significantly contribute to revenue in 2024, forecasting an additional RMB3.5-3.6 billion from these products [2]. - CSPC's R&D expenses rose by 21.2% year-over-year to RMB4.83 billion, indicating a strong commitment to innovation [2]. Financial Performance Summary - **Revenue**: FY23 revenue was RMB31.45 billion, with projections of RMB34.80 billion for FY24E, representing a 10.6% growth [3][9]. - **Net Profit**: FY23 attributable net profit was RMB5.87 billion, with expectations of RMB6.68 billion in FY24E, a 13.7% increase [3][9]. - **Gross Profit Margin**: The gross profit margin decreased to 70.5% in FY23 from 71.9% in FY22, with expectations of 70.3% in FY24E [3][10]. Sales Performance - **Finished Drugs**: Sales of finished drugs increased by 4.6% year-over-year to RMB25.64 billion, although there was a slight decline in the second half of FY23 due to anticorruption measures in China [2]. - **CNS Products**: CNS products saw a 12.1% year-over-year growth, primarily driven by strong sales of NBP [2]. - **Oncology Products**: Sales of oncology products fell by 16.4% year-over-year, largely due to a significant price cut for Keaili [2]. New Product Pipeline - CSPC has several new products expected to drive sales growth, including Mingfule, Yiluoda, and Anfulike, with management forecasting substantial revenue contributions from these products in 2024 [2][3]. - The company has had four drugs added to the National Reimbursement Drug List (NRDL) since early 2024, enhancing market access [2]. Valuation Metrics - The report provides a DCF valuation of RMB7.76 per share, with a WACC of 11.78% and a terminal growth rate of 2.0% [4][10]. - The P/E ratio is projected to decrease from 13.0x in FY23 to 10.5x in FY24E, indicating potential undervaluation [3][10].

PDD Holdings (PDD US) PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE MORE REPORTS FROM BLOOMBERG: RESP CMBR OR http://www.cmbi.com.hk1 | --- | --- | --- | --- | --- | --- | |--------------------------------|----------|----------|----------|-----------|-----------| | (YE 31 Dec) | FY22A | FY23A | FY24E | FY25E | FY26E | | Revenue (RMB mn) | 130,558 | 247,639 | 389,619 | 492,359 | 540,111 | | Net profit (RMB mn) | 31,538.1 | 60,026.5 | 83,882.9 | 118,906.4 | 127,694.3 | | Adjust ...

Investment Rating - The report maintains a "BUY" rating for Kuaishou, with a target price of HK$97, implying an upside of 85.6% from the current price of HK$52.25 [2][3]. Core Insights - Kuaishou is expected to see margin improvement driven by gains in advertising and e-commerce. The company reported solid 4Q23 results, with revenue growth of 15% YoY and a net profit of RMB4.4 billion, which was 34% above consensus estimates [2][3]. - For FY24E, total revenue is projected to grow by 10.6% YoY, with specific segments showing varied performance: livestreaming revenue is expected to decline by 8%, while advertising and other services are forecasted to grow by 20% and 24% YoY, respectively [2][3]. - The adjusted net profit margin (NPM) improved to 13.4% in 4Q23, exceeding estimates, primarily due to a higher-than-expected gross profit margin (GPM) and reduced losses from overseas operations [2][3]. Financial Summary - Revenue for FY23A was RMB113.47 billion, with a YoY growth of 20.5%. For FY24E, revenue is expected to reach RMB125.54 billion, reflecting a growth of 10.6% [3][16]. - The adjusted net profit for FY23A was RMB10.27 billion, with projections for FY24E at RMB16.03 billion, indicating a significant growth of 56.1% YoY [3][16]. - The report highlights a projected GPM of 53.1% for FY24E, with an expected operating profit of RMB13.17 billion, marking a substantial recovery from previous losses [3][16]. Segment Performance - In 4Q23, the revenue breakdown showed online marketing services growing by 24% YoY, while live streaming remained flat at 0% growth. Other services and e-commerce saw significant growth of 36% and 31% YoY, respectively [2][7]. - For 1Q24E, advertising revenue is expected to increase by 26% YoY, while e-commerce GMV is projected to grow by 29% YoY, indicating strong momentum in these segments [2][3]. Valuation Metrics - The report provides a SOTP-based valuation, with the target price set at HK$97, based on a P/E ratio of 24x for FY24E and 17x for FY25E [2][3]. - The current market capitalization is reported at HK$2.27 billion, with a P/S ratio of 1.7 for FY24E, indicating a favorable valuation compared to historical performance [4][16].